StockDuty ← Dashboard Nov 15, 2026 12:24 PM ET
SignalEarnings

$RANI (Rani Therapeutics Holdings) — 8-K: RANI Q3 FY26: Revenue $2M, Net Loss Widens to $9M

RANI
$0.53
+0.21%
Rani Therapeutics reported Q3 FY26 revenue of $2M, driven by $1.7M in contract revenue from the Chugai collaboration versus none in the prior-year period. Net income was -$9M, with net loss widening to $8.8M from $7.9M a year ago as R&D expenses rose to $6.0M on higher compensation costs.
Rani Therapeutics reported Q3 FY26 revenue of $2M, driven by $1.7M in contract revenue from the Chugai collaboration versus none in the prior-year period. Net income was -$9M, with net loss widening t
Sources